Bcl-X L is a Bcl-2-related survival protein that is essential for normal development. Bcl-X L expression is rapidly induced by a wide range of survival signals and many cancer cells constitutively express high levels. The Bcl-X gene has a complex organization with multiple promoters giving rise to RNAs with alternate 5 0 non-coding exons. Here we have investigated the mechanisms that control basal and induced expression of Bcl-X L in B-lymphoma cells. Antisense experiments demonstrated that Bcl-X L was essential for survival of Akata6 B-lymphoma cells. The levels of RNAs containing the IB Bcl-X non-coding exon, derived from the distal 1B promoter, correlated with basal expression of Bcl-X L in primary malignant B cells and this promoter was highly active in B-cell lines. The activity of this promoter was largely dependent on a single Ets binding site and Ets family proteins were bound at this promoter in intact cells. CD40 ligand (CD40L)-induced cell survival was associated with increased Bcl-X L expression and accumulation of exon IA-containing RNAs, derived from the proximal 1A promoter. Nuclear factor-kappaB (NF-jB) inhibition prevented induction of Bcl-X L protein and exon IA-containing RNAs by CD40L. Therefore, the distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells, whereas NF-jB plays a central role in the induction of Bcl-X L in response to CD40 signalling via the proximal 1A promoter.
Introduction
Bcl-X L is an essential antiapoptotic Bcl-2 family protein.
The expression of Bcl-X L is induced by a wide range of survival factors, including CD40, interleukins, hormone receptors and cell adhesion (Grad et al., 2000; Deverman et al., 2002; Sevilla et al., 2001) , and both transcriptional and post-translational control mechanisms for Bcl-X L have been described (Glasgow et al., 2000; Wu et al., 2005) . Bcl-X-deficient mice die at around embryonic day 13 due to extensive apoptosis of neurons and haematopoietic cells (Motoyama et al., 1995) , and Bcl-X is also required for B-cell development and normal lymphoid cell survival (Motoyama et al., 1995; Chao and Korsmeyer, 1998) .
Bcl-X L is also thought to play an important role in the inappropriate survival of malignant cells. Bcl-X L is overexpressed in many human malignancies, including haematopoietic tumours, colorectal, stomach, prostate, breast and ovarian carcinomas (Krajewska et al., 1996a, b; Xerri et al., 1996; Olopade et al., 1997; Pallis et al., 1997; Tu et al., 1998; Lohmann et al., 2000) and is associated with progressive, chemoresistant cancers and poor prognosis (Deng et al., 1998; Friess et al., 1998; Tu et al., 1998; Lohmann et al., 2000; Biroccio et al., 2001) . Overexpression of Bcl-X L promotes tumour formation in mouse model systems (Naik et al., 1996; Pena et al., 1998) and Bcl-X L is activated by retroviral insertions in murine leukaemias .
The Bcl-X gene contains two coding exons (II and III) that are spliced to generate RNAs encoding Bcl-X L , generally the most abundant Bcl-X isoform expressed in cells. Alternate splicing of exons II and III gives rise to at least four additional Bcl-X isoforms (Bcl-X S , Bcl-X DTM , Bcl-Xb and Bcl-Xg), some of which may promote apoptosis by antagonizing the function of Bcl-X L and Bcl-2 (Boise et al., 1993; Ban et al., 1998) .
The promoter region of the Bcl-X gene is complex and contains multiple promoters which are associated with various non-coding exons that contribute to the 5 0 -untranslated region (UTR) of Bcl-X RNAs. In the human, RNAs encoding Bcl-X proteins are thought to initiate close to the 5 0 end of exon II, or at the beginning of exons IA or IB, two non-coding exons, which are spliced to exon II (Grillot et al., 1997; MacCarthy-Morrogh et al., 2000) (Figure 1 ). Bcl-X RNAs contain exon IA or IB, but not both. These different RNAs are thought to arise from the activity of distinct promoter sequences and the genomic sequences upstream of exons IB (referred to in this paper as promoter 1B, p1B) and II (promoter 2, p2) possess strong transcriptional activity (Grillot et al., 1997; MacCarthyMorrogh et al., 2000) . The putative promoter upstream of exon 1A is referred to as promoter 1A (p1A).
The role of the multiple promoters and their associated exons in controlling Bcl-X L expression remains unclear. Previous studies have suggested that the presence of alternate Bcl-X non-coding exons modulates downstream splicing giving rise to alternate Bcl-X protein isoforms (Pecci et al., 2001) . However, we have identified Bcl-X L encoding RNAs containing either upstream exon (i.e., IA or IB) and there does not appear to be an obligate link between the presence of alternate non-coding exons and downstream splicing events in the systems we have studied. The different 5 0 non-coding sequences may influence Bcl-X expression by altering the efficiency of mRNA translation, but there is no evidence to support this idea.
It is also possible that there is no inherent functional difference in transcripts derived from the alternate promoters and that they simply reflect the use of various upstream promoters. Indeed, we previously hypothesized that the presence of alternate Bcl-X promoters may present an elegant solution enabling the cells to integrate the diverse signalling pathways that modulate expression of this gene (MacCarthy-Morrogh et al., 2000) .
The mechanisms that drive Bcl-X expression in response to survival signals have been relatively well studied (Grad et al., 2000; Sevilla et al., 2001) . Previous studies have demonstrated roles for nuclear factorkappaB (NF-kB), Ets and signal transducers and activators of transcription (STAT) transcription factors in activation of Bcl-X expression via the p1A and/or p2 promoters in response to specific cytokines and costimulatory molecules. However, the mechanisms mediating the constitutive expression of Bcl-X in malignant cells, and the transcription factors that act at the distal 1B promoter, are less well understood. Here we have analysed the mechanisms controlling expression of Bcl-X L via alternate promoter usage in malignant human B cells.
Results
Role of Bcl-X L in survival of malignant B cells Although Bcl-X L is often highly expressed in human B-cell malignancies (Xerri et al., 1996) , its functional significance is not fully understood. For example, multiple myeloma cells express Bcl-X L but are not dependent on its expression for survival (Derenne et al., 2002) . We therefore used an antisense approach to determine specifically whether Bcl-X L was required for survival in Akata6 (Burkitt's lymphoma cells), which express relatively high levels of both Mcl-1 and Bcl-X L (but not other Bcl-X isoforms) (Spender et al., 1999) . The structure of part of the human Bcl-X gene is shown. The distal (IB) and proximal (IA) non-coding exons and part of the first coding exon (II) containing the Bcl-X L ATG are shown. Part of the Bcl-X L coding sequence is shown in black. The position of the boundaries for each exon relative to the translation start site is shown. The three potential Bcl-X promoters (p1B, p1A and p2) are indicated. (Middle) Bcl-X RNAs. Major Bcl-X RNAs derive from promoters p1B or p1A and contain exons IB or IA (but not both), or upstream of exon II. Note that alternately spliced RNAs have also been described and precise transcription start sites have not been determined in all cases. (Bottom) Bcl-X promoter constructs analysed in this study. The indicated genomic fragments, containing various Bcl-X promoter regions, were cloned upstream of the luciferase reporter gene (see Materials and methods). The boundaries of the promoter regions relative to the translation start site are shown.
Bcl-X L expression in B-cell lymphoma F Habens et al We used two Bcl-X L antisense oligodeoxynucleotides (AS ODN 15999 and 16011) which had previously been selected as the most potent of a series of Bcl-X L AS ODN and shown to interfere effectively with the expression of Bcl-X L RNA and protein (Taylor et al., 1999; Fennell et al., 2001; Heere-Ress et al., 2002) . As a control, we used an orphan ODN. At 24 h following transfection, the expression of Bcl-X L protein was reduced by B50% in cells transfected with either AS ODN, but not the orphan ODN, compared to mocktransfected control cells (Figure 2a) . The maximum transfection efficiency of Akata6 cells by electroporation is B50%. Therefore, although the observed effects were partial, the AS ODNs were relatively effective in decreasing Bcl-X L expression. Both Bcl-X L AS ODN triggered apoptosis, as demonstrated by significantly increased poly-(ADP-ribose) polymerase (PARP) cleavage in these cells (Po0.005, Student's t-test compared to orphan control transfected cells; Figure 2b ). Therefore, reducing Bcl-X L expression is sufficient to promote Akata6 apoptosis.
Expression of Bcl-X L in human malignant lymphocytes Multiple promoters can drive Bcl-X L expression. We previously demonstrated that Bcl-X RNAs containing exon IB derived from the distal promoter were highly expressed in a subset of primary human malignant B cells (MacCarthy-Morrogh et al., 2000) . To compare the expression of Bcl-X RNAs with alternate non-coding 5 0 exons, we isolated highly purified B cells from a small sample of primary malignancies and compared Bcl-X L protein expression and levels of Bcl-X RNAs. The samples studied comprised chronic lymphocytic leukaemia (CLL; CLL1 and 2) and non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL; NHL1 and 2), diffuse large B-cell lymphoma (DLBCL; NHL3 and 4) and mantle cell lymphoma (MCL; NHL5) (Figure 3a) . Although the numbers of samples are too small to draw conclusions about the relationship between Bcl-X L expression and different malignancy types, the expression of Bcl-X L protein was variable, with highest levels in DLBCL and MCL and lower levels in CLL and FL. Bcl-X S expression was not detected in any of the samples.
To determine the expression of distinct Bcl-X RNAs, we performed semiquantitative polymerase chain reaction (PCR) analysis using primers to specifically amplify exon IA-or IB-containing RNAs (Figure 3b ). The expression of exon IA-containing RNAs was relatively constant between samples (maximal variation six-fold). By contrast, the levels of exon IB-RNAs were more variable (30-fold). There was a relatively close correlation between levels of IB-RNAs and Bcl-X L expression; cells with high levels of Bcl-X L protein generally had high levels of exon IB-containing RNAs. The exception was NHL4, which had abundant Bcl-X L protein, but very low levels of IB-RNAs. Multiple products were obtained in the exon IB-specific PCR, consistent with variation in the precise splice sites use to link the 3 Bcl-X L expression in B-cell lymphoma F Habens et al of exon IB and the 5 0 end of exon II. We have previously characterized some of these variant transcripts (MacCarthy-Morrogh et al., 2000) , but the presence of additional products in the PCRs suggests further uncharacterized splicing linking these exons. Therefore, in primary malignant B cells, variable Bcl-X L expression is relatively closely correlated with the expression of exon IB-containing RNAs. Additional Bcl-X RNAs may initiate close to exon 2, but it is not possible to detect specifically these by reverse transcription (RT)-PCR and the primary material yielded insufficient material for primer extension analysis.
We used reporter assays to compare directly the activity of different Bcl-X promoter regions in B-cell lines. We generated luciferase reporter constructs containing approximately 500 bp of genomic sequence upstream of the 5 0 ends of exons IA (p1A), IB (p1B) and II (p2) (Figure 1 ). We also generated a construct spanning sequences upstream of exon IA, exon II and the intervening intron (p1A2). The STAT binding site previously implicated in response to cytokines (Dumon et al., 1999; Kirito et al., 2002) was contained with the p2 fragment and the NF-kB binding site (Lee et al., 1999; Chen et al., 2000) was present in both p1A þ 2 and p2. The constructs were transfected into Akata6 cells and luciferase activity determined ( Figure 4a ). As demonstrated previously (MacCarthy-Morrogh et al., 2000) , the genomic region containing p1B was highly active in these cells; cells transfected with the p1B reporter plasmid expressed 281737-fold more luciferase than cells transfected with the pGL2-Basic control plasmid (mean of 11 separate determinations7s.e.m.). By contrast, although a construct containing a similar region upstream of exon IA (p1A) was active, it was much less active than p1B possessing on average 1477% of the activity of promoter p1B. The region containing p2 was also relatively highly active in Akata6 cells. The larger genomic fragment containing both p1A and p2 (p1A þ 2) was approximately as active as the p2 fragment alone, suggesting that the major transcriptional-enhancing elements within the B1300 bp upstream of the Bcl-X antithymocyte globulin (ATG) are contained within this relatively small fragment (À346 to À17).
Similar results were obtained in Bcl-X L -positive RPMI-8226 cells (multiple myeloma), with the p1B fragment expressing 2578-fold more luciferase than cells transfected with the pGL2-Basic control plasmid (Figure 4b ). Again p1A was much less active than p1B (mean activity 1271%, relative to p1B). However, in contrast to Akata6 cells, promoter regions containing p2 or both p1A and p2 (p1A þ 2) were relatively inactive in these cells. Therefore, the p1B promoter region is particularly active in malignant B cells.
Role of Ets proteins in Bcl-X promoter activity
The factors that drive the activity of the distal Bcl-X p1B are not known. Sequence analysis of p1B revealed the presence of a candidate transcription factor binding sites for Ets proteins, a family of approximately 20 transcription factors that interact with related DNA sequences (reviewed by Seth and Watson, 2005) . The candidate binding site was identical to the consensus binding site for Ets1 and Ets2, the best studied family members, and was conserved in the mouse (Figure 4c ). We therefore generated deletion mutants of the p1B promoter, and introduced a mutation within the putative Ets binding site that had previously been shown to prevent effectively Ets binding (Tamir et al., 1999) , to define key transcription factors required for its activity.
Deletion of the 5 0 289 bp of the promoter region (in p1B 290À680 ) had no significant effect on promoter activity (Figure 4d ). By contrast, deletion of an additional 120 bp at the 3 0 of the genomic region (in p1B 290À560 ), which contained the putative Ets binding site decreased promoter activity to 1676% (mean of two separate experiments, each in duplicate7s.d.). Importantly, introduction of point mutations directly within the Ets binding sequence within the context of the full-length p1B construct decreased promoter activity by B90% (Figure 4d ), demonstrating that Ets proteins play a major role in controlling the activity of this promoter.
To confirm the importance of Ets proteins for the activity of the p1B promoter, we transfected cells with an expression plasmid encoding the Ets1 DNA-binding domain (DBD), which can act as a dominant negative and interfere with the activity of endogenous Ets proteins. Overexpression of Ets DBD significantly decreased the activity of the p1B promoter, to a similar
Figure 3 Expression of Bcl-X RNA and protein primary malignant B-lymphocytes. Primary malignant B cells were isolated from CLL or NHL biopsies and analysed for expression of (a) Bcl-X L protein by immunoblotting and (b) exon IA-and IB-containing Bcl-X RNAs. b-Actin protein and GAPDH RNA were analysed as controls, respectively. In (b), water was used in place of cDNA as a negative control for PCRs and care was taken to reduce the number of cycles used to obtain a semiquantitative result. The same samples were used previously for the analysis of Mcl-1 expression (Michels et al., 2004) . NHL1 and 2 ¼ follicular lymphoma; NHL3 and 4 ¼ diffuse large B-cell lymphoma and NHL5 ¼ mantle cell lymphoma.
Bcl-X L expression in B-cell lymphoma F Habens et al extent as mutation of the Ets binding site (>80%) (Figure 4e ). Ets proteins have previously been implicated in the regulation of other Bcl-X promoters, although specific response elements have not been identified. Consistent with this Ets, DBD had relatively modest effects on the activity of the p1A and p2 promoter constructs, decreasing expression by 49716 and 2477%, respectively (Figure 4e ). The activity of the control promoter pGL2-Basic was unaffected by co-transfection of Ets DBD. We used chromatin immunoprecipitation (ChIP) assays to confirm that Ets family proteins were associated with the proximal Bcl-X promoter in intact cells. The Bcl-X Ets site would be predicted to bind a wide range of specific Ets family proteins (reviewed by Hsu et al., 2004) . Consistent with this Ets1 and Ets2, as well as other Ets family proteins, Elk and Elf, were associated with the 1B promoter in Akata6 cells ( Figure 5 ). Similar results were found in Ramos B cells (data not shown).
Regulation of Bcl-X promoters by CD40 ligand
In addition to the constitutive expression of Bcl-X L in malignant B cells, Bcl-X L expression can be increased by survival signals, such as CD40 ligand (CD40L) (Choi et al., 1995; Ishida et al., 1995; Wang et al., 1995; Tuscano et al., 1996) . Although various factors have been implicated in the regulation of Bcl-X L in response to CD40 ligation (in particular NF-kB, which is potently activated by CD40 signalling), the role of alternate promoters has not been addressed. We therefore investigated the effects of recombinant trimeric CD40L on Bcl-X L expression and promoter activity.
CD40L rendered Akata6 cells relatively resistant to etoposide-induced apoptosis (Figure 6a ) and reproducibly caused a B2-fold increase in Bcl-X L expression (Figure 6b, lanes 1 and 2) . Exon-specific RT-PCR analysis demonstrated that CD40L increased expression of exon IA-containing RNAs within 4 h, whereas exon IB RNAs were relatively unaffected (Figure 6c ). Finally, we tested the effect of inhibition of NF-kB on the Figure 5 ChIP of Bcl-X p1B. ChIP analysis was performed using Akata6 cells and antibodies specific for Ets1, Ets 2, ELF and ELK, or a control antibody as indicated. Precipitated DNA was amplified using primers specific for the proximal Bcl-X promoter. Water was used in place of precipitated DNA as a negative control and genomic DNA was amplified as a positive control. For each PCR reaction, products were analysed after 30 and 40 cycles. M, molecular weight markers.
Bcl-X L expression in B-cell lymphoma F Habens et al induced and constitutive expression of Bcl-X L . Kamebakaurin interferes with DNA binding by the p50 NF-kB subunit (Lee et al., 2002) and prevented the increase in Bcl-X L expression in CD40L-treated Akata6 cells and induction of exon IA-containing RNAs ( Figure 6 ). By contrast, the basal expression of Bcl-X L in Akata6 cells and expression of exon IB-containing RNAs was not affected by NF-kB inhibition. Similar results were obtained with the I kappa B kinase inhibitor sulphasalazine (data not shown).
Discussion
Bcl-X L is a key member of the Bcl-2 family of apoptosis regulators that is essential for normal development and function of the immune system and is strongly implicated in the inappropriate survival of a range of malignant cells. Our results confirm that Bcl-X L expression is required for survival of Burkitt's lymphoma cells, at least in vitro, demonstrating that these cells are a relevant model system to investigate the molecular mechanisms that control Bcl-X L expression. The genomic organization of the Bcl-X gene is complex with multiple promoter regions that can drive expression of RNAs encoding various Bcl-X isoforms. In the human, two non-coding exons have been identified and additional RNAs are thought to initiate close to the 5 0 end of exon II. The situation may be even more complex in the mouse where at least two more non-coding exons have been described (Pecci et al., 2001) and each non-coding exon is presumed to be associated with an independent promoter region. The significance of these multiple promoter regions is not clear. Previous studies have suggested that the presence of alternate Bcl-X non-coding exons modulates downstream splicing (Pecci et al., 2001 ). However, Bcl-X L is the only isoform expressed in the malignant B cells that we have studied and we have identified Bcl-X L encoding RNAs containing either upstream exon (i.e., IA or IB). Therefore, although distinct 5 0 -UTR may be linked to alternate isoform expression in other systems, in malignant B cells, various Bcl-X RNAs appear to contribute to the overall expression of Bcl-X L .
Bcl-X L was expressed at variable levels in a panel of highly purified primary B-cell malignancies. The levels of expression of exon IB-containing RNAs were more variable than exon IA-containing RNAs and were more closely correlated with expression of Bcl-X L , consistent with the idea that the 1B promoter was particularly active in various malignant B-cell lines. However, it is important to recognize that additional RNAs initiating close to the 5 0 end of exon 2 may also contribute to Bcl-X L expression. Because these RNAs do not contain a unique 5 0 sequence, they cannot be detected specifically by RT-PCR. We were unable to obtain sufficient material for alternate analyses (e.g., primer extension).
Although several studies have shown that the 1B promoter is active in various cell types, the transcription factors that act at this promoter have not been identified. Here we have demonstrated that the activity of the p1B promoter was almost completely dependent on a single binding site for Ets family proteins and that various Ets family proteins bound to the p1B promoter in intact cells. Ets family proteins play a critical role in survival of B cells, and like Bcl-X L , the expression of specific family members is tightly controlled during B-cell development. Ets-mediated control via the distal promoter may therefore play an important role in determining Bcl-X L expression during lymphoid development. Ets has previously been implicated in the regulation of Bcl-X L expression (Grad et al., 2000; Sevilla et al., 2001) . However, these studies did not identify precise response elements and it is possible that at least some of the observed effects of Ets protein overexpression on Bcl-X L expression are mediated via activation of p1B, rather than the proximal promoter sequences, implicated in previous studies (Sevilla et al., 1999) . Similarly, ablation of Ets has been shown to Bcl-X L expression in B-cell lymphoma F Habens et al lead to the downregulation of Bcl-X L and apoptosis (de Nigris et al., 2001) , and regulation via the proximal promoter may have mediated these effects. The Ets binding sites in the distal promoter region may be important for repression mediated by the Ets-family repressor molecule, TEL (Irvin et al., 2003) . A recent study identified other transcriptional control regions within this region which appeared to play an important role in controlling Bcl-X L expression in response to erythropoietin (Tian et al., 2003) . This region lay immediately 5 0 to but did not encompass the Ets site identified in this study and the authors were unable to identify the cell proteins that interacted with these sequences.
A second promoter construct, contained with the p1A2 fragment and comprising proximal promoter sequences (À1303 to À17), was also highly active in Akata6 cells, but not in RPMI-8226 cells. The majority of the transcriptional-promoting activity associated with this region was contained within the p2 promoter fragment, consistent with the identification of a powerful 57 bp promoter region immediately upstream of exon II (Grillot et al., 1997) . However, the STAT binding site, implicated in the induction of Bcl-X L expression in response to specific cytokines is also present in the p2 promoter fragment and may contribute to the activity of this region. The major NF-kB binding sites in the Bcl-X gene were present in p1A2, but not p2. Data presented in this paper show that NF-kB does not appear to contribute to the basal expression of Bcl-X L in these cells, consistent with the lack of effects of NF-kB inhibitors on Bcl-X L expression in the absence of CD40. However, this is in contrast to observations made in Ramos and Daudi B-cell lines (Jazirehi et al., 2004; Vega et al., 2005) . Additional NF-kB binding sites have been identified in the mouse and human Bcl-X promoters (Glasgow et al., 2000) , but these lie upstream of exon IA and are not contained in p2.
In contrast to constitutive expression, the induction of Bcl-X L by CD40L in these cells was associated with an increase in the abundance of exon IA, but not IB-containing RNAs. Although the increase in Bcl-X L expression was modest, it was associated with a significant reduction in sensitivity to etoposide-induced apoptosis. Consistent with previous findings (Lee et al., 1999; Andjelic et al., 2000) , this regulation was dependent on NF-kB. It appears that CD40 signalling triggers the activation of NF-kB, which stimulates the activity of the 1A promoter via NF-kB binding sites present upstream (Glasgow et al., 2000) or downstream (Lee et al., 1999) of exon IA. However, it is also possible that NF-kBmediated CD40 signalling also increases the level of exon II-initiated RNAs. We attempted to determine directly the effect of CD40 activation on each of the cloned Bcl-X promoter regions in transfection experiments. However, we found that various transfection procedures appeared to interfere with the signal-transduction function of the CD40 receptor preventing us from determining, which promoter regions (and specific binding sites) were responsive to CD40 signalling.
Here we have shown that the multiple Bcl-X promoters differentially respond to distinct signals within a single-cell type (Figure 7 ). Ets-mediated activation of the distal Bcl-X promoter plays a central role in the constitutive expression of Bcl-X L in malignant lymphocytes, consistent with the inhibition of extracellular signal-regulated kinase 1/2 signalling and basal Bcl-X L expression in Ramos cells treated with Rituximab (Jazirehi et al., 2004) . Activation of the proximal promoter by NF-kB plays a central role in mediating the response to CD40L. Consistent with the idea that different promoters respond to distinct signals, Viegas et al. (2004) have recently shown that another distal promoter which lies approximately 3.5 kb upstream of the Bcl-X ATG mediates induction of Bcl-X L expression in response to glucocorticoids and progestins. Thus, distinct Bcl-X promoter regions appear to coordinate the very wide range of diverse signalling pathways that control Bcl-X L expression.
Materials and methods

Cell culture
Akata6 cells (Burkitt's lymphoma) were a kind gift from Professor Paul Farrell (Imperial College, London, UK) and were derived by single-cell cloning of the original Akata cell line (Takada et al., 1991; Inman et al., 2001) . Akata6 cells were maintained in RPMI-1640 medium supplemented with 10% (v/v) foetal calf serum (PAA, Yeovil, UK) and antibiotics. RPMI-8226 cells were obtained from American Type Culture Collection and were maintained as for Akata6 cells. Recombinant, trimeric leucine zipper-tagged human CD40L was a kind gift from Immunex Corporation (Seattle, WA, USA) and was used at 1 mg/ml throughout. Kamebakaurin (inhibitor of p50 DNA-binding activity; Lee et al., 2002) was from Calbiochem (Darmstadt, Germany).
Primary malignant B cells were obtained with Local Research Ethics Committee approval (Southampton & SW Hants LREC Number 158/00). NHL samples were purified from malignant lymph node biopsies by negative selection using the B-cell isolation kit (Miltenyi Biotec, Surrey, UK) as described (Dallman and Packham, 2005) . CLL cells were isolated by negative selection from involved spleens. Cells were cultured in B-cell medium (Iscove's modified Dulbecco's Bcl-X L expression in B-cell lymphoma F Habens et al medium supplemented with 10% (v/v) heat-inactivated and filtered human serum, 2 mM L-glutamine/penicillin/streptomycin, 20 mg/ml gentamycin) and maintained at 371C and 5% CO 2 atmosphere in a humidified incubator. The proportion of B cells in the purified sample and expression of immunoglobulin light chains was determined by flow cytometry. Purified samples were >97% B cells (except NHL3, 94% and CLL2, 83%) and malignant samples were light chain restricted.
Western blotting
Western blotting was performed as described previously (Brimmell et al., 1998) . Primary B cells were solubilized directly in SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer at a concentration of 5 Â 10 5 cells/15 ml. Samples were sonicated and heated to 951C for 5 min before loading on an SDS-PAGE. Antibodies used were rabbit anti-b-actin (Sigma, Poole, UK; 20-33), rabbit anti-Bcl-X L (R&D Systems, Oxford, UK; AF800), mouse anti-PARP (R&D Systems; C2.10) and mouse anti-proliferating cell nuclear antigen (PCNA) (Cancer Research UK Research Services, UK; PC10).
AS ODN
20-Mer 2
0 -O-methoxyethyl chimeric antisense oligonucleotides were obtained from Isis Pharmaceuticals (Carlsbad, CA, USA), to inhibit Bcl-X L expression (AS ODN 15999 TCC CGG TTG CTC TGA GAC AT and 16011 CTG GAT CCA AGG CTC TAG GT; Taylor et al., 1999; Heere-Ress et al., 2002 ). An orphan ODN (129688; ttc gcg gct gga cga ttc ag) with no known target sequence was used as a negative control. Akata6 cells were transfected with ODN as described previously (Michels et al., 2004) .
RT-PCR
Total RNA was extracted using Trizol (Invitrogen, Paisley, UK) and converted to cDNA using Moloney murine leukaemia virus RT and oligo-dT primers (Promega, Southampton, UK) according to the manufacturers' instructions. cDNA was amplified using primers Bcl-X IAF (5 0 -CTGAGCTTCGCAA TTCC) and Bcl-X IIIR (5 0 -GGTCTCCATCTCCGATTC) for exon IA-containing RNAs, primers Bcl-X IBF (5 0 -AAGTGAC TGAGCTTGCAAGT) and Bcl-X IIIR for exon IB-containing RNAs and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) F (5 0 -CCACCCATGGCAAATTCCATGGCA) and GAPDH R (5 0 -TCTAGACGGCAGGTCAGGTCC ACC) for GAPDH. HotGoldStar DNA Polymerase (Oswel, Southampton, UK) was used for for exon IA and GAPDH PCRs and Taq polymerase (Promega) and a manual hot start strategy was used for exon IB PCRs. The number of PCR cycles was decreased until a faint band was observed by agarose gel electrophoresis in order to obtain a semiquantitative result.
Plasmids
Plasmid p1B
1À680 contains a 680 bp genomic DNA fragment surrounding the putative start site for exon IB-containing RNAs. To generate p1B 1À680 , a plasmid containing the human 1B Bcl-X promoter (MacCarthy-Morrogh et al., 2000) was amplified using primers N-TD3-5 0 (CCGCTCGAGCGCCTG TAAACGATTCTCCT) and N-TD3-3 0 (CCCAAGCTTCGG CCTCAGTTTCCCCTG), the PCR product was digested with XhoI and HindIII and cloned in to pGL2-Basic (Promega) that had been linearized with the same enzymes. Deletion mutant p1B 290À680 was generated by cloning an RsaI-HindIII fragment of p1B 1-680 into pGL2-Basic linearized with SmaI and HindIII. Deletion mutant p1B 290À560 was generated by blunt end cloning cloning an RsaI-AvaII fragment of p1B 290À680 into pGL2-Basic linearized with SmaI. Plasmid p1A, containing Bcl-X p1A (Figure 1) , was generated by amplifying human placental genomic DNA with primers p1AF (CGAGCTCGAGAA GCCGCTAGG) and p1AR (CAAGCTTCAGAAGGCGA CACAGGAAATTGC), digesting the PCR product with XhoI and HindIII and cloning in to pGL2-Basic that had been linearized with the same enzymes. Plasmid p2 containing the Bcl-X p2 was generated by amplifying human genomic DNA with primers P2F (CCTCGAGAAGGCATTTCGGAGAA GACGG) and P2R (CAAGCTTGGCTCAACCAGTCCATT GTCC), digesting the PCR product with XhoI and HindIII and cloning in to pGL2-Basic that had been linearized with the same enzymes. Plasmid p1A2 was generated by amplifying human genomic DNA with primers P1AF and P2R, digesting the PCR product with XhoI and HindIII and cloning in to pGL2-Basic that had been linearized with the same enzymes. The b-galactosidase expression plasmid, pCMV b-Gal, was from Invitrogen. Electroporation of Akata6 cells, and luciferase and b-galactosidase assays were performed as described previously (MacCarthy-Morrogh et al., 2000) . RPMI-8226 cells (1 Â 10 6 ) were transfected using FugeneHD reagent (Roche, Lewis, UK) as per the manufacturer's instructions at a ratio of 3:1 (Fugene (ml):DNA (mg)).
Chromatin immunoprecipitation
Cells (1 Â 10 7 ) were incubated with 1% (v/v) formaldehyde for 10 min at room temperature. Following neutralization with glycine (0.125 M) and washing with phosphate-buffered saline, cells were lysed in ChIP buffer (1% (w/v) SDS, 5 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl (pH 8.0)) and DNA sheared by sonication. Chromatin was then diluted 1:10 with chromatin dilution buffer (1% (v/v) Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0)). Lysates were cleared by incubating with 2 mg/ml sheared salmon sperm DNA, 0.2% (v/v) pre-immune serum and protein A sepharose (20 ml of 50% slurry per 1 ml lysate) for 2 h at 41C. The lysates were centrifuged, supernatants collected and incubated overnight with 0.5 mg/ml of antibody at 41C. The antibodies used were rabbit anti-Ets1 (N-276), rabbit anti-Ets2 (C-20), rabbit anti-Elk (I-20) and rabbit antiElf (C-20), all from Santa Cruz Inc. (Santa Cruz, CA, USA). An irrelevant rabbit antibody was used as a control. Salmon sperm DNA (2 mg/ml) and protein A sepharose (20 ml of 50% slurry per 1 ml lysate) was added and incubated for a further hour at 41C. Beads were collected by centrifugation and washed sequentially for 10 min in 1 ml each of TSE I (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 150 mM NaCl), TSE II (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 500 mM NaCl), TSE III (0.25 M LiCl, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 1 mM EDTA, 10 mM Tris (pH 8.1)) and TE (10 mM Tris-HCl (pH 8.0)z, 1 mM EDTA). DNA was eluted from beads using 100 ml elution buffer (1% (w/v) SDS, 0.1 M NaHCO 3 , 2.5 ml/mg proteinase K) and crosslinking reversed by heating to 651C for 3 h. DNA was phenol-chloroform extracted and ethanol precipitated before amplification using primers spanning the Ets binding site in Bcl-X p1B (5 0 -GCCT CCCGATTCCCCAGATC and 5 0 -CGGTAGCTTCCAGAC GCAAGAGC).
